194 related articles for article (PubMed ID: 35864174)
21. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
22. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
[TBL] [Abstract][Full Text] [Related]
23. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
Wu D; Jia HY; Wei N; Li SJ
Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
[TBL] [Abstract][Full Text] [Related]
24. SRC-3 coactivator regulates cell resistance to cytotoxic stress via TRAF4-mediated p53 destabilization.
Yi P; Xia W; Wu RC; Lonard DM; Hung MC; O'Malley BW
Genes Dev; 2013 Feb; 27(3):274-87. PubMed ID: 23388826
[TBL] [Abstract][Full Text] [Related]
25. TRAF4-SMURF2-mediated DAZAP2 degradation is critical for IL-25 signaling and allergic airway inflammation.
Zepp JA; Wu L; Qian W; Ouyang W; Aronica M; Erzurum S; Li X
J Immunol; 2015 Mar; 194(6):2826-37. PubMed ID: 25681341
[TBL] [Abstract][Full Text] [Related]
26. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
27. Ubiquitination of tumor necrosis factor receptor-associated factor 4 (TRAF4) by Smad ubiquitination regulatory factor 1 (Smurf1) regulates motility of breast epithelial and cancer cells.
Wang X; Jin C; Tang Y; Tang LY; Zhang YE
J Biol Chem; 2013 Jul; 288(30):21784-92. PubMed ID: 23760265
[TBL] [Abstract][Full Text] [Related]
28. PKCα Attenuates Jagged-1-Mediated Notch Signaling in ErbB-2-Positive Breast Cancer to Reverse Trastuzumab Resistance.
Pandya K; Wyatt D; Gallagher B; Shah D; Baker A; Bloodworth J; Zlobin A; Pannuti A; Green A; Ellis IO; Filipovic A; Sagert J; Rana A; Albain KS; Miele L; Denning MF; Osipo C
Clin Cancer Res; 2016 Jan; 22(1):175-86. PubMed ID: 26350262
[TBL] [Abstract][Full Text] [Related]
29. TRAF4, a new substrate of SIAH1, participates in chemotherapy resistance of breast cancer cell by counteracting SIAH1-mediated downregulation of β-catenin.
Ren H; Mi X; Zhao P; Zhao X; Wei N; Huang H; Meng Z; Kou J; Sun M; Liu Y; Zhang H; Yang J; Li W; Li H
Breast Cancer Res Treat; 2020 Sep; 183(2):275-289. PubMed ID: 32671611
[TBL] [Abstract][Full Text] [Related]
30. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
[TBL] [Abstract][Full Text] [Related]
31. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
Huang Y; Fu P; Fan W
Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
[TBL] [Abstract][Full Text] [Related]
32. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
33. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
Joshi JP; Brown NE; Griner SE; Nahta R
Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.
Mukohara T
Cancer Sci; 2011 Jan; 102(1):1-8. PubMed ID: 20825420
[TBL] [Abstract][Full Text] [Related]
35. TRAF4 Inhibits the Apoptosis and Promotes the Proliferation of Breast Cancer Cells by Inhibiting the Ubiquitination of Spindle Assembly-Associated Protein Eg5.
Hao M; Zhang J; Sun M; Diao K; Wang J; Li S; Cao Q; Dai S; Mi X
Front Oncol; 2022; 12():855139. PubMed ID: 35692762
[TBL] [Abstract][Full Text] [Related]
36. High expression of TRAF4 predicts poor prognosis in tamoxifen-treated breast cancer and promotes tamoxifen resistance.
Zhou J; Li W; Ming J; Yang W; Lu L; Zhang Q; Ruan S; Huang T
Anticancer Drugs; 2020 Jul; 31(6):558-566. PubMed ID: 32304412
[TBL] [Abstract][Full Text] [Related]
37. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
38. A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer.
Menyhárt O; Santarpia L; Győrffy B
Curr Cancer Drug Targets; 2015; 15(8):665-83. PubMed ID: 26452383
[TBL] [Abstract][Full Text] [Related]
39. TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling.
Iyengar PV; Marvin DL; Lama D; Tan TZ; Suriyamurthy S; Xie F; van Dinther M; Mei H; Verma CS; Zhang L; Ritsma L; Ten Dijke P
Mol Cancer Res; 2022 Oct; 20(10):1516-1531. PubMed ID: 35731212
[TBL] [Abstract][Full Text] [Related]
40. TRAF4 mediates activation of TGF-β signaling and is a biomarker for oncogenesis in breast cancer.
Zhou F; Li F; Xie F; Zhang Z; Huang H; Zhang L
Sci China Life Sci; 2014 Dec; 57(12):1172-6. PubMed ID: 25249198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
